Top

Published in:

01-03-2008 | Case Report

Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS

Authors: Yuji Nozaki, Yasuaki Nagare, Koji Kinoshita, Fumiaki Urase, Masanori Funauchi

Published in: Rheumatology International | Issue 5/2008

Abstract

We report a case of rheumatoid arthritis (RA) complicated by myelodysplastic syndrome (MDS) successfully treated by tacrolimus. A 57-year-old woman had persistent pain and swelling in bilateral wrist and knee joints, in addition to severe anemia and leukopenia. She was diagnosed with MDS and RA based on the results of bone marrow aspiration and the criteria of RA. Combination therapy with tacrolimus (1.5 mg day⁻¹) and prednisolone (10 mg day⁻¹) improved her bicytopenia and polyarthralgia.

Thomson AW, Bonham CA, Zeevi A (1995) Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 17:584–591, ReviewPubMedCrossRef

Thomson AW, Bonham CA, Zeevi A (1995) Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 17(6):584–591, ReviewPubMedCrossRef

Kawai S, Yamamoto K (2006) Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford) 45:441–444CrossRef

Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56:690–692PubMedCrossRef

Boultwood J, Lewis S, Wainscoat JS (1994) The 5q-syndrome. Blood 84:3253–3260PubMed

Castro M, Conn DL, Su WP, Garton JP (1991) Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 18:721–727PubMed

Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K (2004) Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 34:423–426PubMed

Uhlig T, Haavardsholm EA, Kvien TK (2006) Comparison of the health assessment questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. Rheumatology (Oxford) 45:454–458CrossRef

George SW, Newman ED (1992) Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum 21:345–354, ReviewPubMedCrossRef

10.

Bagby GC Jr, Gabourel JD, Linman JW (1980) Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Intern Med 92:55–58PubMed

11.

Nelson JL, Hansen JA (1990) Autoimmune diseases HLA. Crit Rev Immunol 10:307–328PubMed

12.

Nakao S, Yamaguchi M, Saito M, Yasue S, Shiobara S, Matsuda T, Nitta M, Sasaki M (1992) HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol 40:239–240PubMedCrossRef

13.

Okamoto T, Okada M, Yamada S, Takatsuka H, Wada H, Tamura A, Fujimora Y, Takemoto Y, Kakishita E (2000) Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele. Leukemia 14:344–346PubMedCrossRef

14.

Biesma DH, van den Tweel JG, Verdonck LF (1997) Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79:1548–1551PubMedCrossRef

15.

Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440PubMedCrossRef

16.

Alexandrakis M, Coulocheri S, Xylouri I, Ganotakis E, Eliakis P, Karkavitsas N, Eliopoulos GD (1998) Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes. Haematologia (Budap) 29:13–24

17.

Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD (2002) Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 15:474–482CrossRef

Title: Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS
Authors: Yuji Nozaki
Yasuaki Nagare
Koji Kinoshita
Fumiaki Urase
Masanori Funauchi
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 5/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-007-0445-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab

Ochronosis with cardiovascular involvement: a case report

Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment

The relation of hand functions with radiological damage and disease activity in rheumatoid arthritis

Effect of a modified S-form hip brace, WISH type, for patients with painful osteoarthritis of the hip: a role in daily walking as a hip muscle exercise

High-frequency sensorineural hearing loss in patients with ankylosing spondylitis: is it an extrarticuler feature of disease?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page